Is A Fall Imminent For Biogen Stock After A 30% Rise In A Month?
6/10 05:31
Biogen stock (NASDAQ: BIIB) has seen a substantial 32% rise in a month, significantly outperforming the broader S&P500 index, down 8%. The rise for Biogen, in particular, can be attributed to success with its Alzheimer’s treatment – Lecanemab – in late-sta...